Inhibrx Biosciences Inc (INBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 200 | 1,800 | 2,192 | 7,231 | 12,888 |
| Gross Profit | 200 | 1,800 | 2,192 | 7,231 | 12,888 |
| Operating Expenses | 331,648 | 221,021 | 131,309 | 83,795 | 80,331 |
| Operating Income | -331,448 | -219,221 | -129,117 | -76,564 | -67,443 |
| Interest Expense | 13,491 | 31,840 | 18,181 | 5,216 | 10,816 |
| Other Income | 2,032,513 | 9,703 | 2,075 | 14 | 2,138 |
| Pre-tax Income | 1,687,574 | -241,358 | -145,223 | -81,766 | -76,121 |
| Income Tax | 2 | 3 | 3 | 2 | 3 |
| Net Income Continuous | 1,687,572 | -241,361 | -145,226 | -81,768 | -76,124 |
| Net Income | $1,687,572 | $-241,361 | $-145,226 | $-81,768 | $-76,124 |
| EPS Basic Total Ops | 114.01 | -5.12 | -3.62 | -2.15 | -3.01 |
| EPS Basic Continuous Ops | 114.01 | -5.12 | -3.62 | -2.15 | -3.01 |
| EPS Diluted Total Ops | 112.62 | -5.12 | -3.62 | -2.15 | -3.01 |
| EPS Diluted Continuous Ops | 112.62 | -5.12 | -3.62 | -2.15 | -3.01 |
| EPS Diluted Before Non-Recurring Items | 112.62 | -5.12 | -3.62 | -2.15 | -3.01 |
| EBITDA(a) | $-329,163 | $-213,131 | $-124,444 | $-74,135 | $-56,235 |